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ABSTRACT
Objective: We hypothesise that low 25-hydroxyvitamin
D (25(OH)D) levels before hospitalisation are associated
with increased risk of acute respiratory failure.
Design: Retrospective cohort study.
Setting: Medical and Surgical Intensive care units of
two Boston teaching hospitals.
Patients: 1985 critically ill adults admitted between
1998 and 2011.
Interventions: None.
Measurements and main results: The exposure of
interest was prehospital serum 25(OH)D categorised as
≤10 ng/mL, 11–19.9 ng/mL, 20–29.9 ng/mL and
≥30 ng/mL. The primary outcome was acute respiratory
failure excluding congestive heart failure determined by
International Classification of Diseases Ninth Edition
(ICD-9) coding and validated against the Berlin
Definition of acute respiratory sistress syndrome.
Association between 25(OH)D and acute respiratory
failure was assessed using logistic regression, while
adjusting for age, race, sex, Deyo-Charlson Index and
patient type (medical vs surgical).
In the cohort, the mean age was 63 years, 45% were
male and 80% were white; 25(OH)D was ≤10 ng/mL in
8% of patients, 11–19.9 ng/mL in 24%, 20–29.9 ng/mL
in 24% and ≥30 ng/mL in 44% of patients. Eighteen
per cent (n=351) were diagnosed with acute respiratory
failure. Compared to patients with 25(OH)D ≥30 ng/mL,
patients with lower 25(OH)D levels had significantly
higher adjusted odds of acute respiratory failure
(≤10 ng/mL, OR=1.84 (95% CI 1.22 to 2.77);
11–19.9 ng/mL, OR=1.60 (95% CI 1.19 to 2.15);
20–29.9 ng/mL, OR=1.37 (95% CI 1.01 to 1.86)).
Conclusions: Prehospital 25(OH)D was associated
with the risk of acute respiratory failure in our critically
ill patient cohort.
INTRODUCTION
In the USA, every year, 190 600 patients
develop acute respiratory distress syndrome
(ARDS), with 74 500 associated deaths and
2.2 million days in the intensive care unit
(ICU).1 Incidences of ARDS among patients
with acute illness and mechanically ventilated
patients are 7% and 11–23%, respectively.2
Although critical care outcomes in general
and those associated with acute respiratory
failure have improved over time, long-term
outcomes of ICU survivors has gained prom-
inence.3 4 Among the more than 100 000
patients who survive ARDS each year, many
develop cognitive abnormalities, depression,
post-traumatic stress disorders and have poor
health-related quality of life.1 5
Recent evidence suggests that vitamin D is a
key regulator of the innate and adaptive
immune system.5 Serum 25-hydroxyvitamin D
(25(OH)D) is the major circulating metabol-
ite of vitamin D, the standard measure of
vitamin D status and is used to assess thera-
peutic response to supplementation. Low
serum 25(OH)D levels are associated with
increased risk of viral and bacterial infections
as well as sepsis possibly due to effects on
innate and adaptive immunity.6 7 Additionally,
vitamin D modulates inflammation, fibrosis
and airway destruction in the lung which
are major steps in ARDS pathogenesis.8 9
Further, decreased muscle strength and mass
is associated with vitamin D deficiency.10
Recent data from a randomised controlled
KEY MESSAGES
▸ Vitamin D deficiency prior to hospitalization is
associated with development of acute respiratory
failure.
▸ Vitamin D deficient patients who develop acute
respiratory failure have heightened mortality.
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Critical care
trial on high-dose vitamin D in critically ill patients
(VITdAL-ICU trial) shows as a secondary outcome the
improved survival in patients with severe vitamin D defi-
ciency (25(OH)D≤12 ng/mL) who receive vitamin D.11
Data are lacking with regards to the association of prehos-
pitalisation vitamin D inadequacy and incident ARDS
during critical illness.
Given that vitamin D inadequacy, defined by measur-
ing circulating 25(OH) D3 levels, is increasingly preva-
lent in the general population of the USA and
associated with critical care outcomes, we performed a
two-centre observational study of adult patients among
whom 25(OH)D concentrations had been measured
for routine clinical reasons within 1 year before hospital-
isation.7 12–23 The objective of this study was to test
the hypothesis that vitamin D status before hospital
admission is inversely associated with the risk of develop-
ing acute respiratory failure in a critically-ill patient
cohort.
MATERIALS AND METHODS
Data on all patients admitted to two teaching hospitals in
Boston between 4 August 1998 and 12 January 2011 were
obtained through a computerised registry. During the
study period, there were 79 927 patient ICU admissions
to the hospitals under study. Approval for the study was
granted by the Partners Human Research Committee
(Institutional Review Board). Requirement for consent
was waived as the data were analysed anonymously. The
cohort included patients ≥18 years of age who received
critical care and had serum 25(OH)D measured between
7 and 365 days before hospitalisation. We excluded
patients with congestive heart failure (International
Classification of Diseases Ninth Edition (ICD-9) 428.0–
428.9) diagnosed following hospital admission.24 The
exposure of interest was serum 25(OH)D level obtained
7 to 365 days prior to the date of hospital admission and
categorised as 25(OH)D <10 ng/mL; 10–19.9 ng/mL;
20–29.9 ng/mL and ≥30 ng/mL.14 We define prehospital
serum 25(OH)D concentration <20 ng/mL as vitamin D
inadequacy, as suggested by a recent Institute of
Medicine report.25 In cases where a patient had serum 25
(OH)D measured more than once in the year prior to
hospitalisation, the serum 25(OH)D measured closest to
the date of hospital admission was utilised.
Race was either self-determined or designated by a
patient representative/healthcare proxy. Patient admission
‘type’ was defined as ‘medical’ or ‘surgical’ and incorpo-
rates the Diagnostic-Related Grouping (DRG) method-
ology.26 We utilised the Deyo-Charlson Index to assess the
burden of chronic illness which is well studied and vali-
dated.27 Sepsis was defined by the presence of any of the
following ICD-9-clinical modification (CM) codes 038.0–
038.9, 020.0, 790.7, 117.9, 112.5 or 112.8128, 3 days prior to
critical care initiation to 7 days after critical care initiation,
a definition validated in our administrative data.7 To deter-
mine neighbourhood socioeconomic disadvantage we
used geocoded residential address data29 from electronic
health records; we then linked the zip+4 data to the Area
Deprivation Index developed by Singh et al30 and linked to
the 2000 US census by Kind et al.31
During the study period between 1998 and 2011, the
chemiluminescence assay, the radioimmunoassay or
liquid chromatography-mass spectroscopy (LC-MS) were
employed at different times as a 25(OH)D assay method.
Dates, times and type of 25(OH)D assay were recorded.
The 25(OH)D assays were tested for imprecision by the
clinical laboratories at the two hospitals. Imprecision
testing with human serum specimens showed within-run
coefficients of variation (CVs) of ≤4.5% for the chemilu-
minescence assay, ≤10.8% for the radioimmunoassay, and
≤8.6% for LC-MS.6
The primary end point was acute respiratory failure
defined by Cooke et al24 and identified by the presence
of ICD-9, codes for respiratory failure or pulmonary
oedema (518.4, 518.5, 518.81 and 518.82) and mechan-
ical ventilation (96.7×), excluding congestive heart
failure (428.0–428.9) following hospital admission.24
Inclusion of mechanical ventilation codes and the exclu-
sion of heart failure codes increases the specificity of the
ICD-9 code combination for ARDS.32 In subanalyses, the
acute respiratory failure end point was validated against
the Berlin Definition of ARDS.33 The secondary end
point was 90-day all-cause mortality obtained from the
Social Security Administration Death Master File. One
hundred per cent of the cohort had at least 90-day
follow-up. The censoring date was 5 January 2012.
Power calculations and statistical analysis
In the cohort under study, the incidence of acute
respiratory failure was 18%. By assuming acute respira-
tory failure incidence in patients with prehospital serum
25(OH)D >30 ng/mL to be 18% and an OR of 1.5 for
incident acute respiratory failure in patients with prehos-
pital serum 25(OH)D ≤30 ng/mL, we needed 359
patients with 25(OH)D >30 ng/mL and 359 patients
with 25(OH)D ≤30 ng/mL to achieve 80% power and
5% significance.
Unadjusted associations between vitamin D groups and
outcomes were estimated by bivariable logistic regression
analysis. Adjusted ORs were estimated by multivariable
logistic regression models with inclusion of covariate
terms chosen based on the biological plausibility of pos-
sible confounding of the vitamin D—acute respiratory
failure association. For the primary model, specification
of each continuous covariate was adjudicated by the
empiric association with the primary outcome using
Akaike’s Information Criterion; the overall model fit was
assessed using the Hosmer Lemeshow test. Models for
secondary analyses (90-day mortality) were specified iden-
tically to the primary model in order to achieve greatest
analogy. Sensitivity analysis were performed for patients
with 25(OH)D measured at various time points prior to
hospital admission. Locally weighted scatter plot smooth-
ing (LOWESS) was used to graphically represent the rela-
tionship between prehospital 25(OH)D concentration
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and rate of acute respiratory failure. A multivariable
Cox’s proportional hazards model was used to illustrate
the survival among patients with acute respiratory failure
as vitamin D intake increases. All p values presented are
two-tailed; values below 0.05 were considered to be sig-
nificant. All analyses are performed using STATA 12.0MP
(College Station, Texas, USA).
To validate the accuracy of ICD-9-CM and current
procedural terminology (CPT)-defined acute respiratory
failure assignment in our study, 206 of the 1985 cohort
patients were chosen at random. Subject charts were
retrospectively reviewed by two clinician investigators
blinded to the subject 25(OH)D level and ICD-9-CM/
CPT acute respiratory failure code assignment to deter-
mine if patients had clinical criteria for ARDS in the
first 14 days of an ICU admission according to the Berlin
definition: (1) acute respiratory failure not fully
explained by cardiac failure or fluid overload, per the
intensivist of record; (2) bilateral opacities consistent
with pulmonary oedema on the chest radiograph or the
CT scan; and (3) onset within 1 week after a known clin-
ical insult or new or worsening respiratory symptoms.33
The validation criteria were met if the criteria for mild,
moderate or severe ARDS, as defined by The Berlin
Definition of ARDS, were achieved in the first 14 days of
an ICU admission: mild if PaO2/FiO2=201–300 mm Hg,
moderate if PaO2/FiO2=101–200 mm Hg and severe if
PaO2/FiO2 ≤100 mm Hg with PEEP level ≥5 cm H2O
was present in all ARDS cases. Diagnosis of ARDS was
established by consensus of the two clinician investiga-
tors and resolved by a third in case of discrepancies.
RESULTS
Table 1 shows demographic characteristics of the parent
ICU cohort and the study cohort. Differences between
the parent and study cohorts included gender, patient
type and comorbidity. In the study cohort (N=1985),
most patients were women, white and had medical-
related DRG with a mean age of 63 years. The mean
(SD) 25(OH)D in the study cohort was 29.0 (15.5) ng/
mL which did not statistically differ by season of 25(OH)
D draw (p=0.12, χ2). The majority of 25(OH)D measure-
ments in the study cohort occurred within 6 months of
hospital admission (20% within 1 month, 48% within
3 months and 72% within 6 months). Most study cohort
patients had 25(OH)D levels ≥20 ng/mL (8% with 25
(OH)D <10 ng/mL; 24% with 10–19.9 ng/mL; 24% with
20–29.9 ng/mL and 44% with ≥30 ng/mL). The 90-day
mortality of the study cohort was 15.7%.
In the study cohort, the most common Major
Diagnostic Codes in the cohort by system were circula-
tory 31.7%, digestive 14%, musculoskeletal 8.9%,
kidney 8.4%, endocrine 7.7%, respiratory 4.8%, injuries
4.4% and infectious 4.2%. The mean (SD) time from
hospital admission to acute respiratory failure diagnosis
was 1.46 (4.43) days and the mean (SD) time from
hospital admission to ICU admission was 1.90 (6.19)
days. Validation of ICD-9-CM/CPT-defined acute respira-
tory failure assignment, as per the Berlin Definition
of ARDS, showed that ICD-9-CM/CPT-defined acute
respiratory failure assignment had a sensitivity of 59.4%
(95% CI 46.4 to 71.5%), a specificity of 95.1% (95% CI
90.1 to 97.9%), a positive predictive value of 84.4%
Table 1 Characteristics of total ICU cohort (N=77 927) and study cohort (N=1985)
Total ICU cohort Study cohort
N 79 927 1985
Age-mean(SD) 61.8 (18.3) 63.2 (16.2)
Sex number (%)
Female 33 556 (42) 1083 (55)
Male 46 371 (58) 902 (45)
Race number (%)
White 63 712 (80) 1602 (81)
Non-white 16 215 (20) 383 (19)
Patient type number (%)
Medical 39 355 (49) 1372 (69)
Surgical 40 572 (51) 613 (31)
Deyo-charlson index number (%)
0–3 56 312 (70) 1227 (62)
4–6 19 060 (24) 553 (28)
>6 4555 (6) 205 (10)
Body mass index-mean(SD)* 27.3 (6.9) 27.3 (7.7)
Area deprivation index-mean(SD)† 86.0 (32.8) 81.8 (30.4)
Sepsis number (%) 10 215 (13) 231 (12)
Acute respiratory failure number (%) 12 308 (15) 351 (18)
90-day mortality number (%) 13 860 (17) 311 (16)
Greater Area Deprivation Index means a greater disadvantage.
*5527 of the total ICU cohort and 435 study cohort patients had body mass index determined.
†Area Deprivation Index is an ecological measure of socioeconomic disadvantage.
ICU, intensive care unit.
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(95% CI 69.9 to 93.0) and a negative predictive value of
83.9% (95% CI 77.0 to 89.0).
Patient characteristics of the study cohort were strati-
fied according to preadmission vitamin D groups
(table 2). Factors that significantly differed between
stratified groups included age, gender, calcium and
haematocrit. Factors that did not significantly differ
between stratified groups included Deyo-Charlson index,
patient type (surgical vs medical) and season of 25(OH)
D measurement. Table 3 indicates that age, gender and
25(OH)D are significant predictors of acute respiratory
failure in our model.
Primary outcome
Preadmission 25(OH)D was strongly associated with
acute respiratory failure during hospitalisation (table 4).
The odds of acute respiratory failure was 2.1-fold,
1.7-fold and 1.5-fold higher in patients with 25(OH)D
values in the <10 ng/mL, 10–19.9 ng/mL, 20–29.9 ng/
mL groups, respectively, compared to those with 25
(OH)D ≥30 ng/mL. 25(OH)D in the cohort remains a
significant predictor of odds of acute respiratory failure
following adjustment for age, race, sex, Deyo-Charlson
Index and patient type (medical vs surgical). The
adjusted odds of acute respiratory failure was 1.8-fold,
1.6-fold and 1.4-fold higher in patients with 25(OH)D
values in the <10 ng/mL, 10–19.9 ng/mL, 20–29.9 ng/
mL groups, respectively, compared to those with 25
(OH)D ≥30 ng/mL (table 4). LOWESS plot (figure 1)
showed a near inverse linear association between
vitamin D status and an acute respiratory failure rate for
25(OH)D concentrations of approximately 40 ng/mL;
beyond 40 ng/mL, the association appears flat.
Individually running the adjusted model with and
without terms for assay, year, season or sepsis did not
materially affect the acute respiratory failure estimates
reported above (see online supplementary table S1);
thus, the vitamin D-acute respiratory failure relationship
was not materially confounded by these covariates.
Further, utilising 25(OH)D as a continuous variable, we
Table 2 Patient characteristics by prehospital vitamin D status
Prehospital 25(OH)D, ng/mL
<10.0 10–19.9 20–29.9 ≥30 Total
N 164 477 473 871 1985 p Value
Age-mean (SD) 57.3 (16.9) 61.3 (16.6) 62.4 (15.9) 65.9 (15.4) 63.2 (16.2) 0.001*
Sex number (%) 0.01
Female 83 (51) 243 (51) 246 (52) 511 (59) 1083 (55)
Male 81 (49) 234 (49) 227 (48) 360 (41) 902 (45)
Race number (%) <0.0001
White 125 (76) 366 (77) 371 (78) 740 (85) 1602 (81)
Non-white 39 (24) 111 (23) 102 (22) 39 (15) 383 (19)
African–American 17 (10) 43 (9) 34 (7) 34 (4) 128 (6)
Patient type number (%) 0.27
Medical 115 (70) 343 (72) 331 (70) 583 (67) 1372 (69)
Surgical 49 (30) 134 (28) 142 (30) 288 (33) 613 (31)
Deyo-Charlson index number (%) 0.087
0–3 88 (54) 285 (60) 294 (62) 560 (64) 1227 (62)
4–6 59 (36) 135 (28) 137 (29) 222 (25) 553 (28)
>6 17 (10) 57 (12) 42 (9) 89 (10) 205 (10)
Diabetes mellitus number (%) 49 (30) 193 (40) 159 (34) 274 (31) 675 (34) 0.005
Body mass index-mean (SD)† 27.9 (8.2) 28.1 (9.9) 28.0 (6.5) 25.9 (5.9) 27.3 (7.7) 0.064*
Season of 25(OH)D draw number (%) 0.18
Spring 43 (26) 132 (28) 141 (30) 242 (28) 558 (28)
Summer 35 (21) 114 (24) 120 (25) 229 (26) 498 (25)
Winter 38 (23) 119 (25) 103 (22) 162 (19) 422 (21)
Fall 48 (29) 112 (23) 109 (23) 238 (27) 507 (26)
Calcium ≥10.5 mg/dL number (%) 26 (16) 66 (14) 60 (13) 74 (9) 226 (11) 0.003
Haematocrit <30% number (%) 31 (19) 98 (21) 88 (19) 121 (14) 338 (17) 0.009
>90 days between 25(OH)D and Admission
number (%)
56 (34) 192 (40) 264 (56) 516 (59) 1028 (52) <0.001
Area deprivation index-mean (SD) 87.1 (28.1) 84.6 (27.1) 84.1 (28.3) 77.9 (33.2) 81.8 (30.4) <0.001*
Sepsis number (%) 28 (17) 73 (15) 53 (11) 77 (9) 231 (12) 0.001
Sputum culture positivity number (%) 30 (21) 92 (22) 71 (17) 119 (15) 312 (17) 0.01
Acute respiratory failure number (%) 41 (25) 102 (21) 89 (19) 119 (14) 351 (18) <0.001
90-day mortality number (%) 34 (21) 111 (23) 76 (16) 90 (10) 311 (16) <0.001
p Values determined by χ2 unless designated by (*) then p value determined by ANOVA.
Columns may not add up to 100% due to rounding. Greater Area Deprivation Index means a greater disadvantage.
†435 cohort patients had body mass index determined.
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find that for every increase in preadmission 25(OH)D of
5 ng/mL, the odds of acute respiratory failure during
hospitalisation decreases by 8% (OR 0.92, 95% CI 0.88
to 0.96; p<0.001) when adjusted for age, gender, race,
type and Deyo-Charlson index.
We also performed a sensitivity analysis of the timing
of prehospital 25(OH)D draw date. Sensitivity analysis of
the effects of excluding patients with preadmission 25
(OH)D levels obtained ≥30, ≥60, ≥90 or ≥180 days
prior to admission did not materially change the associ-
ation between vitamin D and ICD-9-CM defined acute
respiratory failure (see online supplementary table S2).
A modest attenuation of the effect size was observed as
the time difference increased, but the vitamin D acute
respiratory failure associations retained statistical
significance.
In cohort patients with acute respiratory failure
(n=381), vitamin D status was associated with risk of mor-
tality. Though limited by sample size, patients with
Table 3 Multivariable-adjusted associations between covariates and acute respiratory failure
Acute respiratory
failure Absent*
1634
Acute respiratory
failure Present*
352 p Value† OR‡ 95% CI p Value
Age (per 1 year) 64 (16) 59 (17) <0.001 0.99 0.98 to 0.99 <0.001
Sex 0.002
Male 716 186 1.37 1.09 to 1.74 0.008
Female 918 165 1 Referent
Race 0.22
Non-white 307 (19) 76 (22) 1.10 0.82 to 1.47 0.53
White 1327 (81) 275 (78) 1 Referent
Patient type 0.14
Surgical 493 (70) 120 (66) 1.22 0.95 to 1.57 0.11
Medical 1141 (30) 231 (34) 1 Referent
Deyo-Charlson index 0.012
0–3 1034 (63) 193 (55) 1 Referent
4–6 435 (27) 118 (34) 1.45 1.13 to 1.88 0.004
≥6 165 (10) 40 (11) 1.30 0.89 to 1.90 0.18
25(OH)D§ <0.001
<10 ng/mL 123 (8) 41 (12) 1.84 1.22 to 2.77 0.004
10–19.9 ng/mL 375 (23) 102 (29) 1.60 1.19 to 2.15 0.002
20–29.9 ng/mL 384 (24) 89 (25) 1.37 1.01 to 1.86 0.04
≥30 ng/mL 752 (46) 119 (34) 1.00 Referent
Estimates for each variable are adjusted for all other variables in the table.
*Number (%) shown except for age which is shown as Mean (SD).
†p Values determined by χ2 except age determined by Kruskal-Wallis.
‡OR for acute respiratory failure.
§25(OH)D estimates adjusted for age, race, sex, Deyo-Charlson Index and patient type (medical vs surgical).
Table 4 Unadjusted and adjusted associations between
prehospital 25(OH)D level and acute respiratory failure
OR 95% CI p Value
Unadjusted
25(OH)D
<10 ng/mL 2.11 1.41 to 3.15 <0.0001
10–19.9 ng/mL 1.72 1.28 to 2.30 <0.0001
20–29.9 ng/mL 1.46 1.08 to 1.98 0.01
≥30 ng/mL 1.00 Referent
Adjusted
25(OH)D
<10 ng/mL 1.84 1.22 to 2.77 0.004
10–19.9 ng/mL 1.60 1.19 to 2.15 0.002
20–29.9 ng/mL 1.37 1.01 to 1.86 0.04
≥30 ng/mL 1.00 Referent
CI, OR for acute respiratory failure.
Referent in each case is 25(OH)D ≥30 ng/mL.
Estimates adjusted for age, race, sex, Deyo-Charlson Index and
patient type (medical vs surgical).
Figure 1 Vitamin D status versus acute respiratory failure
Rate. 25(OH)D=25-hydroxyvitamin D. Locally weighted scatter
plot smoothing (LOWESS) utilised to represent the near
inverse linear association between prehospital 25(OH)D
concentration and acute respiratory failure rate. With
bandwidth parameter=0.99, 1919 cohort patients were utilised
to construct the curve.
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prehospital 25(OH)D values of <10 ng/mL, 10–
19.9 ng/mL and 20–29.9 ng/mL had odds of 90-day
mortality of 2.02 (95% CI 0.96 to 4.27; p=0.064), 2.57
(95% CI 1.49 to 4.45; p<0.001) and 1.57 (95% CI 0.89 to
2.80; p=0.12), respectively, compared to those with 25
(OH)D ≥30 ng/mL following adjustments for age, race,
sex, Deyo-Charlson Index and patient type (medical vs
surgical; table 5). Cox proportional-hazards regression
analysis demonstrated that in patients with acute respira-
tory failure, the risk of death declines with each 5 ng/
mL increase in prehospital 25(OH)D adjusted for age,
race, sex, Deyo-Charlson Index and patient type
(medical vs surgical; HR 0.92, 95% CI 0.87 to 0.97;
p=0.004).
Effect modification
Analyses based on fully-adjusted models were performed
to evaluate the 25(OH)D-acute respiratory failure associ-
ation, and p for interaction was determined to explore
for any evidence of effect modification. We individually
tested for effect modification by hospital, time between
25(OH)D draw and hospital admission and season of 25
(OH)D draw by adding an interaction term to the multi-
variate models. Effect modification analysis showed that
the association between 25(OH)D and acute respiratory
failure was not modified by the hospital that provided
care (p interaction=0.19), or the time between 25(OH)
D draw and hospital admission (p interaction=0.30).
When we investigated effect modification by season of
25(OH)D draw, we identified a nearly statistically signifi-
cant interaction term for 25(OH)D and acute respira-
tory failure (p interaction=0.07). When the cohort is
analysed by restricting this to the season of 25(OH)D
draw, the directionality of the association between 25
(OH)D and acute respiratory failure remains, but the
effect size is strongest with 25(OH)D drawn in the
spring season and weakest in the fall.
DISCUSSION
The present, two-centre study aimed to determine
whether suboptimal vitamin D status prior to hospital
admission was associated with acute respiratory failure in
the critically ill. In unadjusted and adjusted analyses, we
found increased odds of acute respiratory failure in
patients with preadmission 25(OH)D <20 ng/mL. In
addition, our mortality analysis suggests that patients
with 25(OH)D levels <20 ng/mL before hospital admis-
sion who develop acute respiratory failure have a higher
risk for mortality compared to patients with prehospital
25(OH)D levels ≥30 ng/mL.
ARDS is due to diffuse alveolar damage mediated by
inflammatory cytokines such as tumour-necrosis factor,
interleukin (IL)-1, IL-6 and IL-8 and subsequent neutro-
phil recruitment and release of oxygen free radicals that
damage capillary endothelium and alveolar epithe-
lium.34 35 Immunomodulatory and proinflammatory
associations of vitamin D deficiency are well known.
Vitamin D induces expression of the gene for cathelici-
din, which promotes intracellular killing of bacteria.36 In
the lung, cathelicidin likely plays a role in mucosal
defence as it is produced by neutrophils, macrophages
and airway epithelium, and upregulated in response to
infection and inflammation.37 These biological observa-
tions indicate the potential importance of vitamin D
status to innate immunity and ARDS.
Prior studies have reported robust associations of
low vitamin D and sepsis, bloodstream infections and
mortality in critically ill adults.13 The VITdAL-ICU trial
secondary outcome data shows high-dose vitamin D sup-
plementation reduces mortality in patients with severe
vitamin D deficiency (25(OH)D≤12 ng/mL), but was
not designed to study respiratory outcomes.11 In the
current study, the reason for an increase in mortality in
acute respiratory failure patients with vitamin D inad-
equacy is likely to be multifactorial. Other issues that
may be important for critical illness outcomes include
vitamin D related effects on vascular endothelial growth
factor, endothelin and the renin-angiotensin-aldosterone
system.38–40 Further, comorbidities including incident
hypertension, glucose intolerance, the metabolic syn-
drome, obesity and cardiovascular disease are all asso-
ciated with low 25(OH)D and higher mortality.41–45
The present study is not without potential limitations.
Observational studies may be limited by bias, confound-
ing, and/or reverse causation.46 Importantly, causality
cannot be determined in our study. Our utilisation of
ICD-9 and CPT coding likely reflects the measured inci-
dence of acute respiratory failure in the cohort rather
than the actual incidence. Ascertainment bias may exist
in our study as the patient cohort under study had
vitamin D status measurements for reasons that may be
absent in other critically ill patients. Despite adjustment
for multiple potential confounders, residual confound-
ing may contribute to the observed differences in out-
comes and vitamin D status could simply be a marker of
baseline healthy behaviours. Specifically, we are unable
Table 5 Unadjusted and adjusted associations between
prehospital 25(OH)D level and 90-day mortality in patients
with acute respiratory failure
OR 95% CI p Value
Unadjusted
25(OH)D
<20 ng/mL 2.19 1.31 to 3.63 0.003
20–29.9 ng/mL 1.37 0.77 to 2.44 0.285
≥30 ng/mL 1.00 Referent
Adjusted
25(OH)D
<20 ng/mL 2.48 1.45 to 4.25 0.001
20–29.9 ng/mL 1.48 0.82 to 2.70 0.195
≥30 ng/mL 1.00 Referent
CI, OR for 90-day mortality. N=381, 90-day mortality 39.9%.
Referent in each case is 25(OH)D ≥30 ng/mL.
<20 ng/mL cut point chosen for power issues. Estimates adjusted
for age, race, sex, Deyo-Charlson Index and patient type (medical
vs surgical). 100% of the cohort had vital status follow-up at
90 days.
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to adjust for immobilisation, excessive alcohol intake,
smoking status, genetic factors, hypertension, low-density
lipoprotein-cholesterol, education level and low milk
consumption all of which can alter 25(OH)D.47 48 The
percentage of cohort patients who are female is 55%
while the percentage of African-Americans is only 6%,
which may limit generalisability. The 25(OH)D-mortality
association appears to be preserved when 25(OH)D is
obtained within 30 days of admission. Despite this obser-
vation, vitamin D levels at the time of hospitalisation
may be different from the levels when prehospital values
were drawn. We also do not have any information as to
why 25(OH)D concentrations were obtained in the
cohort. Finally, our observations may represent a healthy
user effect rather than causality.49
The present study has several strengths. To the best of
our knowledge, our study is the first large sample study
to evaluate an association between prehospital vitamin D
and incident acute respiratory failure. Crucially, we have
sufficient statistical power to detect a clinically relevant
difference in acute respiratory failure between the
vitamin D groups. The exclusion of ICD-9 codes related
to heart failure and requirement of mechanical ventila-
tion ICD-9 codes for our exposure increases the specifi-
city of the codes for ARDS.24 The Deyo-Charlson Index
allowed us to account for chronic medical comorbidities.
Finally, by measuring vitamin D status at least 7 days
prior to hospitalisation, we attempted to uncouple the
influence of acute illness and inflammation on 25(OH)
D levels.
CONCLUSION
In summary, prehospital vitamin D inadequacy (25(OH)
D <20 ng/mL) is associated with incident acute respira-
tory failure during critical illness and death in patients
with acute respiratory failure. Despite our observations,
supplementation of vitamin D in critically ill patients
cannot be advocated for prevention or treatment of
acute respiratory failure as our study does not establish
causation. The data presented in combination with the
hypothesis generating VITdAL-ICU trial data11 does
provide an impetus to perform randomised controlled
trials to determine whether vitamin D supplementation
therapy might have benefit in decreasing the incidence
of or improving outcomes of ARDS in critically ill
patients with low 25(OH)D.
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